Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A S Florjancic

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|March 15, 2002
HMR-3562. Aventis PharmaZ Ma, A S Florjancic
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitorsG S Sheppard, A S Florjancic, J R Giesler, et al.
Journal of Medicinal Chemistry|January 23, 1998
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonistsM L Curtin, S K Davidsen, H R Heyman, et al.
Bioorganic & Medicinal Chemistry Letters|June 20, 2001
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770M L Curtin, A S Florjancic, H R Heyman, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Current Opinion in Investigational Drugs (London, England : 2000)|March 15, 2002
HMR-3562. Aventis PharmaZ Ma, A S Florjancic
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitorsG S Sheppard, A S Florjancic, J R Giesler, et al.
Journal of Medicinal Chemistry|January 23, 1998
Discovery and evaluation of a series of 3-acylindole imidazopyridine platelet-activating factor antagonistsM L Curtin, S K Davidsen, H R Heyman, et al.
Bioorganic & Medicinal Chemistry Letters|June 20, 2001
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770M L Curtin, A S Florjancic, H R Heyman, et al.
Pageof 1